PharmiWeb.com - Global Pharma News & Resources
06-Dec-2022

Kepler Vision Technologies announces first ever hospital deployment with UZ Brussel (University Hospital Brussels)

  • Kepler Vision’s computer vision monitoring solution will be used to help take care of patients at UZ Brussel.
  • Partnership with Belgian leader in patient monitoring solutions Innomediq marks Kepler Vision Technologies’ first deployment in a hospital setting.

Amsterdam, 1st of december 2022 — Global leader in the development of vision-based human activity recognition software Kepler Vision Technologies today announced its partnership with leading Belgian medical device company Innomediq. This partnership will see UZ Brussel (University Hospital Brussels)  use Kepler’s Night Nurse technology to monitor the wellbeing of elderly patients.

The Kepler Night Nurse (KNN) solution is a computer vision-based body language detection system able to detect falls, patient discomfort and when patients have entered areas they are not supposed to. In response, it instantly notifies care staff so that they can respond quickly, minimizing the chance of harm for clients. For example, if an elderly person falls in the night, the AI powered KNN image analysis program will immediately identify when they are on the ground, and send an automated message to staff member alerting them to assist.

This technology outperforms motion sensors, bed mats, and wearable monitoring systems in cutting down false alarms by 99.9%, reducing the unnecessary workload of care staff - while empowering them to more effectively look after the wellbeing of patients.

Kepler’s deployment with UZ Brussel marks the first time the solution has been used in a hospital setting, and next step in Kepler Vision’s international expansion outside of its home country of the Netherlands, and is made possible by Belgium based patient monitoring provider Innomediq. At present Kepler Night Nurse is in use monitoring 9 1-person rooms with ongoing tests to determine the optimal work procedure for 2 double rooms within the hospital.

Dr Harro Stokman, CEO and founder of Kepler Vision said: “This is an extraordinarily exciting period for us at Kepler Vision as we see our cutting-edge patient monitor solution employed in a hospital for the first time. Since the first successful application in a care home environment, we were aware of the wider applications and benefits our technology could provide other medical and healthcare adjacent facilities and organizations, so to see this in practice marks an important next step for us as a business. Our work with UZ Brussel is also an important component of our international expansion, as we continue to bring the benefits of the Kepler Night Nurse solution to care staff and patients around the world in 2023.”

Jan van den Bergh, Innomediq: “The Kepler technology brings a unique and innovative expansion of the possibilities for monitoring the well-being and safety of patients. Within that framework, the Kepler Night Nurse is a wonderful technology which enables us to take patient follow-ups to the next level, and in this way improve the quality of care and patient safety. Within hospitals and beyond, understanding and managing medical alerts is critical to making such a technology successful for both users and patients. Innomediq is specializes in this and is therefore extremely suitable as a partner for all healthcare institutions for such technology.”

Kepler Vision’s Night Nurse solution is the world’s first computer vision-based fall detector to be awarded medical device status. Its computer vision powered software officially registered as a medical device in compliance with the European council directive 93/42/EEC. The registration signifies that the software has been tested both internally and in the field to meet the highest specifications and that risk assessments and mitigating measures have been met. The software encodes seventeen patent applications of which three have been granted, with a further 15 pending.

Editor Details

Related Links

Last Updated: 06-Dec-2022